Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung
- PMID: 15231689
- DOI: 10.1093/carcin/bgh217
Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung
Abstract
Fragile histidine triad (FHIT) gene plays an important role in the pathogenesis of lung cancer. However, the clinicopathological significance of CpG island hypermethylation of FHIT gene in non-small cell lung cancer (NSCLC) remains to be elucidated. We studied FHIT methylation in 254 NSCLCs in order to further understand the clinicopathological and prognostic significance of FHIT methylation in NSCLC. Methylation status of the FHIT gene was examined using Methylation-Specific PCR. All statistical analyses were two-sided, with a 5% type I error rate. Hypermethylation of the FHIT gene occurred more frequently in squamous cell carcinoma than adenocarcinoma. For 93 adenocarcinomas there was no statistically significant association between FHIT methylation and age, gender, smoking history, pathologic stage and p16 methylation. However, FHIT methylation in 125 squamous cell carcinomas was associated with exposure to tobacco smoke and p16 methylation, but not with age, gender and pathologic stage. Hypermethylation of FHIT in squamous cell carcinomas occurred more frequently in current smokers (45%) than in never-smokers (13%). FHIT methylation was significantly associated with p16 methylation in current- and ex-smokers (P = 0.02 and P = 0.01, respectively) with squamous cell carcinoma and in patients with pathologic stage I squamous cell carcinoma (P = 0.001). Patients with p16 methylation were 3.74 times [95% confidence interval (CI) = 1.62 - 7.95; P = 0.001] more likely to have FHIT methylation in squamous cell carcinoma. FHIT methylation in squamous cell carcinoma occurred at a 4.62 times (95% CI = 1.26 - 34.97; P = 0.02) higher prevalence in current smokers than in never-smokers. No prognostic effect of FHIT methylation was observed in stage I and stage II NSCLCs. In conclusion, hypermethylation of the FHIT gene did not have a prognostic significance in early stage NSCLCs. The FHIT methylation is associated with the p16 methylation and smoking in squamous cell carcinoma, suggesting that FHIT may cooperate with p16 for the development of squamous cell carcinoma of lung in individuals exposed to tobacco smoke.
Similar articles
-
The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.Cancer. 2006 May 15;106(10):2190-9. doi: 10.1002/cncr.21870. Cancer. 2006. PMID: 16598757
-
Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.Cancer Res. 2006 Apr 15;66(8):4049-54. doi: 10.1158/0008-5472.CAN-05-3813. Cancer Res. 2006. PMID: 16618724
-
Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.J Clin Oncol. 2004 Jun 15;22(12):2363-70. doi: 10.1200/JCO.2004.10.077. J Clin Oncol. 2004. PMID: 15197197
-
Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.Cancer. 2005 Nov 1;104(9):1825-33. doi: 10.1002/cncr.21409. Cancer. 2005. PMID: 16177988 Review.
-
Molecular genetics of small cell lung carcinoma.Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13. Semin Oncol. 2001. PMID: 11479891 Review.
Cited by
-
Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients.Sci Rep. 2015 Mar 10;5:8897. doi: 10.1038/srep08897. Sci Rep. 2015. PMID: 25754026 Free PMC article.
-
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.Clin Epigenetics. 2015 Mar 17;7(1):29. doi: 10.1186/s13148-015-0065-5. eCollection 2015. Clin Epigenetics. 2015. PMID: 25806091 Free PMC article.
-
DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update.Mol Cancer. 2008 Oct 23;7:81. doi: 10.1186/1476-4598-7-81. Mol Cancer. 2008. PMID: 18947422 Free PMC article. Review.
-
Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis.J Cell Mol Med. 2008 Sep-Oct;12(5A):1495-501. doi: 10.1111/j.1582-4934.2008.00309.x. Epub 2008 Mar 19. J Cell Mol Med. 2008. PMID: 18363846 Free PMC article. Review.
-
Nature's Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization.Curr Med Chem. 2024;31(32):5281-5304. doi: 10.2174/0109298673282525240222050051. Curr Med Chem. 2024. PMID: 38425113 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical